MAIA Biotechnology

Yahoo Finance • 4 days ago

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-... Full story

Yahoo Finance • 12 days ago

MAIA Biotechnology Announces $1.51 Million Private Placement

CHICAGO, IL, Dec. 16, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it ha... Full story

Yahoo Finance • 18 days ago

MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach

CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology (NYSE American: MAIA) – The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade of targeted therapies and checkpoint... Full story

Yahoo Finance • 27 days ago

MAIA Biotechnology Announces Open Market Purchases by CEO and Directors

CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that... Full story

Yahoo Finance • last month

MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025

Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICAGO , Nov. 21, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYS... Full story

Yahoo Finance • 2 months ago

MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-sta... Full story

Yahoo Finance • 3 months ago

MAIA Biotechnology announces $0.74M private placement

* MAIA Biotechnology (NYSE:MAIA) announced [https://seekingalpha.com/pr/20263719-maia-biotechnology-announces-736600-private-placement] that it has entered into definitive agreements for the purchase and sale of an aggregate of 0.60M sha... Full story

Yahoo Finance • 3 months ago

MAIA Biotechnology Announces $736,600 Private Placement

CHICAGO, IL, Oct. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it ha... Full story

Yahoo Finance • 3 months ago

MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets

MAIA’s Board of Directors authorizes holdings of up to 90% of the Company’s liquid assets in cryptocurrencies (BTC), Ethereum (ETH), and USD Coin (USDC) CHICAGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American:... Full story

Yahoo Finance • 3 months ago

Monday 10/6 Insider Buying Report: KMX, MAIA

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is th... Full story

Yahoo Finance • 3 months ago

MAIA Biotechnology announces $2.25 million private placement

* MAIA Biotechnology (NYSE:MAIA [https://seekingalpha.com/symbol/MAIA]) announced on Monday that it has entered into definitive agreements for the purchase and sale of an aggregate of 1.74 million shares of common stock at $1.30 per shar... Full story

Yahoo Finance • 3 months ago

MAIA Biotechnology Announces $2.25 Million Private Placement

CHICAGO, IL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it h... Full story

Yahoo Finance • 3 months ago

Simpson Manufacturing is Oversold

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals a... Full story

Yahoo Finance • 3 months ago

MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent

THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell lung cancer (NSCLC) CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NY... Full story

Yahoo Finance • 4 months ago

MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today highlighted p... Full story

Yahoo Finance • 4 months ago

MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer

Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer (NSCLC) CHICAGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-... Full story

Yahoo Finance • 4 months ago

MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells

CHICAGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that... Full story

Yahoo Finance • 5 months ago

MAIA Biotechnology Reports FDA's Fast Track Designation For Ateganosine

(RTTNews) - MAIA Biotechnology (MAIA) announced that the FDA has granted Fast Track designation for ateganosine for the treatment of non-small cell lung cancer. Ateganosine is currently being evaluated in a Phase 2 THIO-101 clinical trial... Full story

Yahoo Finance • 5 months ago

MAIA Biotechnology's 41% decline validates InvestingPro's overvalued call

When InvestingPro’s Fair Value model flagged MAIA Biotechnology (NYSE:MAIA) as overvalued in April 2024, the clinical-stage biotechnology company was trading at $2.90. Today, the stock trades at $1.69, validating the model’s assessment wit... Full story

Yahoo Finance • 6 months ago

Maia Biotechnology enters stock purchase agreement for up to $587,905 with Prevail Partners

Maia Biotechnology, Inc. (NYSE American:MAIA), a biotechnology company with a market capitalization of $52.7 million, announced it has entered into a stock purchase agreement with Prevail Partners, LLC to issue and sell up to $587,905 of i... Full story